Because MGMT methylation was suggested as a pivotal prognostic factor for OS of glioma patients who were treated with temozolomide[6,17], we established Cox models for all glioblastoma patients, patients treated with temozolomide as well as patients without temozolomide application, respectively. This evidence concerns the gene MGMT and central nervous system cancer.